Modulation of COX-2 expression by statins in human monocytic cells.
Macrophage cyclooxygenase-2 (COX-2) plays an important role in prostaglandin E2 and thromboxane A2 production. Statins are inhibitors of HMG CoA (3-Hydroxy-3-methylglutaryl coenzyme A) reductases and cholesterol synthesis, which block the expression of several inflammatory proteins independent of their capacity to lower endogenous cholesterol. In the present study, we investigated the effect of simvastatin and mevastatin on COX-2 induction in human monocytic cell line U937 and analyzed the underlying mechanisms. Pretreatment of U937 cells with simvastatin or mevastatin for 24 h resulted in a significant reduction in the lipopolysaccharide (LPS)-dependent induction of prostaglandin E2, thromboxane A2 synthesis, and COX-2 expression. Mevalonate, the direct metabolite of HMG CoA reductase, and farnesyl pyrophosphate and geranylgeranyl-pyrophosphate, intermediates of the mevalonate pathway, significantly reversed the inhibitory effect of statins on COX-2. An inhibitor of geranylgeranyl transferases, GGTI-286 mimicked the effect of statins on COX-2 expression. Cytonecrotic factor-1 increased LPS-dependent expression of COX-2. Treatment of cells with NSC 23766, an inhibitor of Rac, which we demonstrated to block Rac 2 activation, resulted in an inhibition of the LPS-dependent expression of COX-2. Whereas no effect was obtained with RhoA/C blocker, C3 exoenzyme. Gel retardation experiments and NFkappaB-p65 transcription factor assay showed that simvastatin and NSC 23766 decrease significantly NF-kappaB complex formation. In macrophages, the antiinflammatory effects of statins are mediated in part through the inhibition of COX-2 and prostanoids. Rac GTPase protein is identified as one of the targets of statins in this regulation.
Habib
Aïda
A
Department of Biochemistry, American University of Beirut, P.O. Box 11-236 Beirut, Lebanon. ah31@aub.edu.lb
Shamseddeen
Ishraq
I
Nasrallah
Mona S
MS
Antoun
Tania Abi
TA
Nemer
Georges
G
Bertoglio
Jacques
J
Badreddine
Rami
R
Badr
Kamal F
KF
D051546:Cyclooxygenase 2 / Q000235:genetics*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008148:Lovastatin / Q000031:analogs & derivatives / Q000494:pharmacology; D008565:Membrane Proteins / Q000235:genetics*; D008798:Mevalonic Acid / Q000378:metabolism; D009000:Monocytes / Q000378:metabolism*; D016328:NF-kappa B / Q000378:metabolism; D019821:Simvastatin / Q000494:pharmacology; D020298:U937 Cells; D020744:rac GTP-Binding Proteins / Q000187:drug effects; D000097766:RAC2 GTP-Binding Protein
D051546:Cyclooxygenase 2; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008070:Lipopolysaccharides; D008148:Lovastatin; D008565:Membrane Proteins; D008798:Mevalonic Acid; D016328:NF-kappa B; D019821:Simvastatin; D020744:rac GTP-Binding Proteins; D000097766:RAC2 GTP-Binding Protein; C012258:mevastatin; C496540:PTGS2 protein, human